Immunotherapeutic approaches to skin cancer.
Topical application of a relatively low concentration of one or more agents to which the patient has previously been sensitized can mobilize cell-mediated immune systems at the site of neoplastic or premalignant lesions. Such treatment has proved to be effective against both primary and metastatic skin lesions. It is also suggested that dermatologic experience may provide a model for other cancer immunotherapies.
D000287:Administration, Topical; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001500:BCG Vaccine; D002280:Basal Cell Carcinoma / Q000628:therapy; D004137:Dinitrochlorobenzene / Q000008:administration & dosage; D006801:Humans; D007111:Immunity, Cellular; D007156:Immunologic Memory; D007167:Immunotherapy; D008264:Macrophages / Q000276:immunology; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage; D011809:Quinones / Q000008:administration & dosage; D012878:Skin Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D013891:Thiouridine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014373:Tuberculin / Q000008:administration & dosage; D014983:Xeroderma Pigmentosum / Q000628:therapy
D000970:Antineoplastic Agents; D001500:BCG Vaccine; D004137:Dinitrochlorobenzene; D009588:Nitrogen Mustard Compounds; D011809:Quinones; D014373:Tuberculin; D013891:Thiouridine